NanoViricides Inc.

02/08/2021 | Press release | Archived content

NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.